NCT06887738View on ClinicalTrials.gov

Study of NM8074 in Patients with Dermatomyositis (DM)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2026

Primary Completion Date

November 30, 2027

Study Completion Date

December 31, 2028

Conditions
Dermatomyositis
Interventions
DRUG

NM8074

NM8074 will be administered as an intravenous infusion at a dose of 20mg/kg

Sponsors
All Listed Sponsors
lead

NovelMed Therapeutics

INDUSTRY